Navigation Links
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
Date:3/7/2012

LA JOLLA, CA - Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

"I am excited that our scientific findings will help save lives," said Charles Cochrane, MD, professor emeritus at Scripps Research. "Many years of work in our basic research laboratory at The Scripps Research Institute made this landmark development possible."

Respiratory distress syndrome (also known as neonatal respiratory distress syndrome) is a life-threatening condition affecting pre-term infants. The more premature an infant is, the more likely he or she is to suffer from it and die.

The condition occurs when infants are born prior to the time when natural surfactant is made in their lungs. Surfactant is a liquid that coats the inside of the lungs, helping to keep the air sacs open and making normal breathing possible. Without enough surfactant, the lungs collapse and the body can be starved of oxygen.

In addition to mechanical ventilation, current treatments for pre-term infants involve using surfactants derived from chopped cow or pig lungs. However, animal-derived surfactants are expensive, contain material that can be injurious to the lungs, and cannot be produced in quantities sufficient to treat pre-term infants worldwide. In addition, animal-derived surfactants can only be used once since they cause an immune reaction; in contrast, the new synthetic surfactant is not immunogenic.

The Cochrane lab first created a synthetic version of surfactant in the 1990s, mimicking a natural peptide known as Surfactant Protein B; the inventors of the technology are Cochrane and Susan Revak. After this formative work at Scripps Research, the therapy was developed by Discovery Labs of Warrington, PA, which oversaw the three phases of clinical trials required by the FDA. These clinic trials provided data on the drug's success.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CESĀ® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... N.J. , Jan. 20, 2017 ... "Company"), a company that provides clinically useful molecular ... it has entered into a securities purchase agreement ... of 855,000 shares of common stock in a ... the Company has agreed to sell to the ...
(Date:1/20/2017)... -- Stock-Callers.com explores the Biotech industry to ... recent performances of select equities. In this morning,s lineup ... Abeona Therapeutics Inc. (NASDAQ: ABEO ), Theravance ... Therapeutics Inc. (NASDAQ: SAGE ). According to ... market size is expected to reach $604.40 billion by 2020 due to ...
(Date:1/19/2017)... 19, 2017  Market Research Future has a half cooked research ... Biopsy is growing rapidly and expected to reach USD 450 Million ... ... Biopsy Market has been assessed as a swiftly growing market and ... in the coming future. There has been a tremendous growth in ...
(Date:1/19/2017)... ... January 19, 2017 , ... November ... to leading biopharmaceutical and medical device manufacturers and regulators, is proud to announce ... Part 11-compliant email client designed to provide product vigilance departments with the flexibility ...
Breaking Biology Technology: